Global Radiocontrast Agent Market By Type (Barium-based Radiocontrast Agent, Iodinated Radiocontrast Agent, Gadolinium-based Radiocontrast Agent, Microbubble Radiocontrast Agent, X-ray/Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasound), By Application (Radiology, Interventional Radiology, and Interventional Cardiology), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029
- 141775
- 20-Dec
- PDF/PPT/Word
-
Report Details
The report on Radiocontrast Agent Market offers in-depth analysis of market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report includes the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global radiocontrast agent market is segmented on the basis of Type, Application, and geography.
The Worldwide market for Radiocontrast Agent Market is expected to grow at a CAGR of roughly x.x% over the next nine years, and will reach US$ XX.X Mn in 2028, from US$ XX.X Mn in 2018, according to a new Market.us (Prudour Research) study.
Radiocontrast Agent Market Scope:
By type, the market is segmented into Barium-based Radiocontrast Agent, Iodinated Radiocontrast Agent, Gadolinium-based Radiocontrast Agent, Microbubble Radiocontrast Agent, X-ray/Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasound. By Application, the market is divided into Radiology, Interventional Radiology, and Interventional Cardiology.
Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), Guerbet (France), Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South Korea), Jodas (India), and Magnus Health (India).Key Market Segments
Type
Barium-based Radiocontrast Agent
Iodinated Radiocontrast Agent
Gadolinium-based Radiocontrast Agent
Microbubble Radiocontrast Agent
X-ray/Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
UltrasoundApplication
Radiology
Interventional Radiology
Interventional CardiologyKey Market Players included in the report:
GE Healthcare (US)
Bracco Imaging (Italy)
Bayer HealthCare (Germany)
Guerbet (France)
Lantheus (US)
Daiichi Sankyo (Japan)
Unijules Life Sciences (India)
J.B. Chemicals and Pharmaceuticals (India)
Spago Nanomedicine (Sweden)
Taejoon Pharm (South Korea)
Jodas (India)
Magnus Health (India)Reasons to Get this Report:
In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Radiocontrast Agent Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Radiocontrast Agent Market; high-growth regions; and market drivers, restraints, and also market chances.
The analysis covers Radiocontrast Agent Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Radiocontrast Agent Market across sections such as also Application and representatives.
Additionally, the analysis also has a comprehensive review of the crucial players on the Radiocontrast Agent Market together side their company profiles, SWOT analysis, latest advancements, and business plans.The analysis objectives of the report are:
To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
To know the Radiocontrast Agent Market by pinpointing its many subsegments.
To profile the important players and analyze their growth plans.
To endeavor the amount and value of Radiocontrast Agent sub-markets, depending on key regions (various vital states).
To analyze Radiocontrast Agent Market concerning growth trends, prospects, and also their participation in the entire sector.
To examine and study the Radiocontrast Agent Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2014 to 2019, and also prediction to 2028.
Primary worldwide Radiocontrast Agent Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market. -
Table Of Content
1. Radiocontrast Agent Market Introduction
1.1. Definition
1.2. Taxonomy
1.3. Research Scope2. Executive Summary
2.1. Key Findings by Major Segments
2.2. Top strategies by Major Players3. Global Radiocontrast Agent Market Overview
3.1. Radiocontrast Agent Market Dynamics
3.1.1. Drivers
3.1.2. Opportunities
3.1.3. Restraints
3.1.4. Challenges3.2. PESTLE Analysis
3.3. Opportunity Map Analysis
3.4. PORTER’S Five Forces Analysis
3.5. Market Competition Scenario Analysis
3.6. Product Life Cycle Analysis
3.7. Opportunity Orbits
3.8. Production Analysis by Region/Company
3.9. Industry chain Analysis
3.10. Marketing Strategy4. Global Radiocontrast Agent Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
4.1. Global Radiocontrast Agent Market Analysis by Type: Introduction
4.2. Market Size and Forecast by Region
4.3. Barium-based Radiocontrast Agent4.4. Iodinated Radiocontrast Agent
4.5. Gadolinium-based Radiocontrast Agent
4.6. Microbubble Radiocontrast Agent
4.7. X-ray/Computed Tomography (CT)
4.8. Magnetic Resonance Imaging (MRI)
4.9. Ultrasound
5. Global Radiocontrast Agent Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
5.1. Global Radiocontrast Agent Market Analysis by Application: Introduction
5.2. Market Size and Forecast by Region
5.3. Radiology5.4. Interventional Radiology
5.5. Interventional Cardiology
6. Global Radiocontrast Agent Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
6.1. North America
6.1.1. North America Radiocontrast Agent Market: Regional Trend Analysis
6.1.1.1. US
6.1.1.2. Canada
6.1.1.3. Mexico6.2.1. Europe
6.2.1. Europe Radiocontrast Agent Market: Regional Trend Analysis
6.2.1.1. Germany
6.2.1.2. France
6.2.1.3. UK
6.2.1.4. Russia
6.2.1.5. Italy
6.2.1.6. Spain
6.2.1.7. Rest of Europe6.3. Asia-Pacific
6.3.1. Asia-Pacific Radiocontrast Agent Market: Regional Trend Analysis
6.3.1.1. China
6.3.1.2. Japan
6.3.1.3. Korea
6.3.1.4. India
6.3.1.5. Rest of Asia-Pacific6.4. Latin America
6.4.1. Latin America Radiocontrast Agent Market: Regional Trend Analysis
6.4.1.1. Brazil
6.4.1.2. Argentina
6.4.1.3. Rest of Latin America6.5. Middle East and Africa
6.5.1. Middle East and Africa Radiocontrast Agent Market: Regional Trend Analysis
6.5.1.1. GCC
6.5.1.2. South Africa
6.5.1.3. Israel
6.5.1.4. Rest of MEA7. Global Radiocontrast Agent Market Competitive Landscape, Market Share Analysis, and Company Profiles
7.1. Market Share Analysis
7.2. Company Profiles
7.3. GE Healthcare (US)7.3.1. Company Overview
7.3.2. Financial Highlights
7.3.3. Product Portfolio
7.3.4. SWOT Analysis
7.3.5. Key Strategies and Developments7.4. Bracco Imaging (Italy)
7.4.1. Company Overview
7.4.2. Financial Highlights
7.4.3. Product Portfolio
7.4.4. SWOT Analysis
7.4.5. Key Strategies and Developments7.5. Bayer HealthCare (Germany)
7.5.1. Company Overview
7.5.2. Financial Highlights
7.5.3. Product Portfolio
7.5.4. SWOT Analysis
7.5.5. Key Strategies and Developments7.6. Guerbet (France)
7.6.1. Company Overview
7.6.2. Financial Highlights
7.6.3. Product Portfolio
7.6.4. SWOT Analysis
7.6.5. Key Strategies and Developments7.7. Lantheus (US)
7.7.1. Company Overview
7.7.2. Financial Highlights
7.7.3. Product Portfolio
7.7.4. SWOT Analysis
7.7.5. Key Strategies and Developments7.8. Daiichi Sankyo (Japan)
7.8.1. Company Overview
7.8.2. Financial Highlights
7.8.3. Product Portfolio
7.8.4. SWOT Analysis
7.8.5. Key Strategies and Developments7.9. Unijules Life Sciences (India)
7.9.1. Company Overview
7.9.2. Financial Highlights
7.9.3. Product Portfolio
7.9.4. SWOT Analysis
7.9.5. Key Strategies and Developments7.10. J.B. Chemicals and Pharmaceuticals (India)
7.10.1. Company Overview
7.10.2. Financial Highlights
7.10.3. Product Portfolio
7.10.4. SWOT Analysis
7.10.5. Key Strategies and Developments7.11. Spago Nanomedicine (Sweden)
7.11.1. Company Overview
7.11.2. Financial Highlights
7.11.3. Product Portfolio
7.11.4. SWOT Analysis
7.11.5. Key Strategies and Developments7.12. Taejoon Pharm (South Korea)
7.12.1. Company Overview
7.12.2. Financial Highlights
7.12.3. Product Portfolio
7.12.4. SWOT Analysis
7.12.5. Key Strategies and Developments7.13. Jodas (India)
7.13.1. Company Overview
7.13.2. Financial Highlights
7.13.3. Product Portfolio
7.13.4. SWOT Analysis
7.13.5. Key Strategies and Developments7.14. Magnus Health (India)
7.14.1. Company Overview
7.14.2. Financial Highlights
7.14.3. Product Portfolio
7.14.4. SWOT Analysis
7.14.5. Key Strategies and Developments8. Assumptions and Acronyms
9. Research Methodology
10. Contact -
Inquiry Before Buying
-
Request Sample
